Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 19

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 liabilities(528)(1,136)Decrease in other operating assets3,527 92 Increase in other operating liabilities— 1,132 Net cash provided by operating activities26,399 18,885 Cash flows from investing activitiesPurchase of marketable securities(30,000)(350,000)Proceeds from sale of marketable securities10,000 — Purchase of property and equipment(712)(761)Net cash used in investing activities(20,712)(350,761)Cash flows from financing activitiesProceeds from exercise of share options6,221 6,052 Proceeds from issue of convertible loan notes— 402,500 Payments for debt issuance costs— (13,358)Net cash provided by financing activities6,221 395,194 Increase in net cash and cash equivalents11,908 63,318 Net foreign exchange difference on cash held20,294 (959)Cash and cash equivalents at beginning of period455,731 442,626 Cash and cash equivalents at end of period$487,933 $504,985 Supplemental disclosure of cash flow informationCash paid for interest$(5,031)$(2,442)Cash paid for income taxes, net of refunds$(1,510)$(59)

The accompanying notes form an integral part of these condensed consolidated financial statements.

6

Table of Contents

Immunocore Holdings plc

Notes to the Condensed Consolidated Financial Statements 

(Unaudited)

1. Description of business

Immunocore Holdings plc (collectively with its subsidiaries, the “Company”) is a public limited company incorporated in England and Wales and has the following wholly owned subsidiaries: Immunocore Limited, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited, Immunocore GmbH, and Immunocore Nominees Limited with operations based primarily in the United Kingdom and United States. The Company is pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX (Immune mobilizing monoclonal TCRs Against X disease) platform, the Company’s pipeline includes clinical and preclinical programs in oncology, infectious diseases, and autoimmune diseases.In January and April 2022, the Company received approval from the U.S. Food and Drug Administration ("FDA") and European Commission ("EC"), respectively, for its lead product, KIM